Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 9 de 9
Filter
1.
J Neonatal Perinatal Med ; 16(3): 507-516, 2023.
Article in English | MEDLINE | ID: mdl-37718859

ABSTRACT

BACKGROUND: Neonates admitted to the neonatal intensive care unit (NICU) are at risk for healthcare-associated infections, including central line-associated bloodstream infections. We aimed to characterize the epidemiology of bloodstream infections among neonates with central venous catheters admitted to three Indian NICUs. METHODS: We conducted a prospective cohort study in three tertiary NICUs, from May 1, 2017 until July 31, 2019. All neonates admitted to the NICU were enrolled and followed until discharge, transfer, or death. Cases were defined as positive blood cultures in neonates with a central venous catheter in place for greater than 2 days or within 2 days of catheter removal. RESULTS: During the study period, 140 bloodstream infections were identified in 131 neonates with a central venous catheter. The bloodstream infection rate was 11.9 per 1000 central line-days. Gram-negative organisms predominated, with 38.6% of cases caused by Klebsiella spp. and 14.9% by Acinetobacter spp. Antimicrobial resistance was prevalent among Gram-negative isolates, with 86.9% resistant to third- or fourth-generation cephalosporins, 63.1% to aminoglycosides, 61.9% to fluoroquinolones, and 42.0% to carbapenems. Mortality and length of stay were greater in neonates with bloodstream infection than in neonates without bloodstream infection (unadjusted analysis, p < 0.001). CONCLUSIONS: We report a high bloodstream infection rate among neonates with central venous catheters admitted to three tertiary care NICUs in India. Action to improve infection prevention and control practices in the NICU is needed to reduce the morbidity and mortality associated with BSI in this high-risk population.


Subject(s)
Catheter-Related Infections , Catheterization, Central Venous , Central Venous Catheters , Cross Infection , Sepsis , Infant, Newborn , Humans , Intensive Care Units, Neonatal , Central Venous Catheters/adverse effects , Prospective Studies , India/epidemiology , Cross Infection/etiology , Catheter-Related Infections/epidemiology , Catheterization, Central Venous/adverse effects
2.
J Hosp Infect ; 136: 1-7, 2023 Jun.
Article in English | MEDLINE | ID: mdl-36907332

ABSTRACT

BACKGROUND: Contact precautions are widely used to prevent the transmission of carbapenem-resistant organisms (CROs) in hospital wards. However, evidence for their effectiveness in natural hospital environments is limited. OBJECTIVE: To determine which contact precautions, healthcare worker (HCW)-patient interactions, and patient and ward characteristics are associated with greater risk of CRO infection or colonization. DESIGN, SETTING AND PARTICIPANTS: CRO clinical and surveillance cultures from two high-acuity wards were assessed through probabilistic modelling to characterize a susceptible patient's risk of CRO infection or colonization during a ward stay. User- and time-stamped electronic health records were used to build HCW-mediated contact networks between patients. Probabilistic models were adjusted for patient (e.g. antibiotic administration) and ward (e.g. hand hygiene compliance, environmental cleaning) characteristics. The effects of risk factors were assessed by adjusted odds ratio (aOR) and 95% Bayesian credible intervals (CrI). EXPOSURES: The degree of interaction with CRO-positive patients, stratified by whether CRO-positive patients were on contact precautions. MAIN OUTCOMES AND MEASURES: The prevalence of CROs and number of new carriers (i.e. incident CRO aquisition). RESULTS: Among 2193 ward visits, 126 (5.8%) patients became colonized or infected with CROs. Susceptible patients had 4.8 daily interactions with CRO-positive individuals on contact precautions (vs 1.9 interactions with those not on contact precautions). The use of contact precautions for CRO-positive patients was associated with a reduced rate (7.4 vs 93.5 per 1000 patient-days at risk) and odds (aOR 0.03, 95% CrI 0.01-0.17) of CRO acquisition among susceptible patients, resulting in an estimated absolute risk reduction of 9.0% (95% CrI 7.6-9.2%). Also, carbapenem administration to susceptible patients was associated with increased odds of CRO acquisition (aOR 2.38, 95% CrI 1.70-3.29). CONCLUSIONS AND RELEVANCE: In this population-based cohort study, the use of contact precautions for patients colonized or infected with CROs was associated with lower risk of CRO acquisition among susceptible patients, even after adjusting for antibiotic exposure. Further studies that include organism genotyping are needed to confirm these findings.


Subject(s)
Cross Infection , Humans , Cross Infection/epidemiology , Cross Infection/prevention & control , Carbapenems/pharmacology , Cohort Studies , Bayes Theorem , Infection Control/methods , Anti-Bacterial Agents/pharmacology , Anti-Bacterial Agents/therapeutic use , Intensive Care Units
3.
J Perinatol ; 38(2): 105-109, 2018 02.
Article in English | MEDLINE | ID: mdl-29120455

ABSTRACT

Hospitalized infants have the highest rates of invasive Staphylococcus aureus disease of any population and infection control strategies such as decolonization have been insufficient. For decades, researchers began studying the microbiome in search of new prevention strategies. The resident microbiota was found to be closely associated with susceptibility and at times, resistance to S. aureus colonization. The evolution of nucleic acid based techniques has enhanced our understanding of the complex relationship between the nasal microbiota and S. aureus colonization. We review what is known about bacterial communities in the nasal cavity of infants and discuss how future microbiome studies may help identify novel interventions to protect high-risk infants from S. aureus disease.


Subject(s)
Microbiota , Nasal Cavity/microbiology , Staphylococcal Infections/prevention & control , Staphylococcus aureus/physiology , Host-Pathogen Interactions , Humans , Infant , Risk Factors
4.
J Hosp Infect ; 95(1): 91-97, 2017 Jan.
Article in English | MEDLINE | ID: mdl-27887754

ABSTRACT

BACKGROUND: Meticillin-resistant Staphylococcus aureus (MRSA) is a leading cause of healthcare-associated infection in the neonatal intensive care unit (NICU). Decolonization may eliminate bacterial reservoirs that drive MRSA transmission. AIM: To measure the association between colonization pressure from decolonized and non-decolonized neonates and MRSA acquisition to inform use of this strategy for control of endemic MRSA. METHODS: An eight-year retrospective cohort study was conducted in a level-4 NICU that used active surveillance cultures and decolonization for MRSA control. Weekly colonization pressure exposures were defined as the number of patient-days of concurrent admission with treated (decolonized) and untreated (non-decolonized) MRSA carriers in the preceding seven days. Poisson regression was used to estimate risk of incident MRSA colonization associated with colonization pressure exposures. The population-attributable fraction was calculated to assess the proportion of overall unit MRSA incidence attributable to treated or untreated patients in this setting. FINDINGS: Every person-day increase in exposure to an untreated MRSA carrier was associated with a 6% increase in MRSA acquisition risk [relative risk (RR): 1.06; 95% confidence interval (CI): 1.01-1.11]. Risk of acquisition was not influenced by exposure to treated, isolated MRSA carriers (RR: 1.01; 95% CI: 0.98-1.04). In the context of this MRSA control programme, 22% (95% CI: 4.0-37) of MRSA acquisition could be attributed to exposures to untreated MRSA carriers. CONCLUSION: Untreated MRSA carriers were an important reservoir for transmission. Decolonized patients on contact isolation posed no detectable transmission threat, supporting the hypothesis that decolonization may reduce patient-to-patient transmission. Non-patient reservoirs may contribute to unit MRSA acquisition and require further investigation.


Subject(s)
Carrier State/epidemiology , Cross Infection/epidemiology , Intensive Care Units, Neonatal , Methicillin-Resistant Staphylococcus aureus/isolation & purification , Staphylococcal Infections/epidemiology , Carrier State/microbiology , Cross Infection/microbiology , Cross Infection/transmission , Disease Reservoirs , Endemic Diseases , Epidemiological Monitoring , Female , Humans , Incidence , Infant , Infant, Newborn , Male , Retrospective Studies , Risk Assessment , Staphylococcal Infections/microbiology , Staphylococcal Infections/transmission
5.
Expert Rev Anti Infect Ther ; 14(1): 95-108, 2016.
Article in English | MEDLINE | ID: mdl-26535959

ABSTRACT

The Centers for Disease Control and Prevention (CDC) defines carbapenem-resistant Enterobacteriaceae (CRE) based upon a phenotypic demonstration of carbapenem resistance. However, considerable heterogeneity exists within this definitional umbrella. CRE may mechanistically differ by whether they do or do not produce carbapenemases. Moreover, patients can acquire CRE through multiple pathways: endogenously through antibiotic selective pressure on intestinal microbiota, exogenously through horizontal transmission or through a combination of these factors. Some evidence suggests that non-carbapenemase-producing CRE may be more frequently acquired by antibiotic exposure and carbapenemase-producing CRE via horizontal transmission, but definitive data are lacking. This review examines types of CRE resistance mechanisms, antibiotic exposure and horizontal transmission pathways of CRE acquisition, and the implications of these heterogeneities to the development of evidence-based CRE healthcare epidemiology policies. In our Expert Commentary & Five-Year View, we outline specific nosocomial CRE knowledge gaps and potential methodological approaches for their resolution.


Subject(s)
Anti-Bacterial Agents/therapeutic use , Bacterial Proteins/genetics , Carbapenems/therapeutic use , Cross Infection/drug therapy , Enterobacteriaceae Infections/drug therapy , Enterobacteriaceae/genetics , beta-Lactam Resistance/genetics , beta-Lactamases/genetics , Bacterial Proteins/metabolism , Communicable Disease Control/methods , Cross Infection/epidemiology , Cross Infection/microbiology , Cross Infection/transmission , Enterobacteriaceae/drug effects , Enterobacteriaceae/enzymology , Enterobacteriaceae Infections/epidemiology , Enterobacteriaceae Infections/microbiology , Enterobacteriaceae Infections/transmission , Epidemiological Monitoring , Gene Expression , Gene Transfer, Horizontal , Humans , Molecular Epidemiology , Mutation , Plasmids/chemistry , Plasmids/metabolism , United States/epidemiology , beta-Lactamases/metabolism
6.
J Perinatol ; 34(11): 805-10, 2014 Nov.
Article in English | MEDLINE | ID: mdl-25010222

ABSTRACT

Staphylococcus aureus (S. aureus) continues to be a leading cause of outbreaks and health-care-associated infections in neonatal intensive care units. In the first few months of life, many neonates acquire S. aureus as part of their delicate and evolving microbiota. Neonates that asymptomatically acquire S. aureus colonization are at increased risk of developing a subsequent S. aureus infection. This review discusses the epidemiology and prevention of S. aureus disease in neonates and how decolonization to eradicate S. aureus may decrease S. aureus transmission and infections in the neonatal intensive care unit.


Subject(s)
Cross Infection/transmission , Intensive Care Units, Neonatal , Staphylococcal Infections/transmission , Anti-Bacterial Agents/therapeutic use , Asymptomatic Diseases , Carrier State , Humans , Infant, Newborn , Mupirocin/therapeutic use , Risk Assessment
7.
J Perinatol ; 33(10): 768-71, 2013 Oct.
Article in English | MEDLINE | ID: mdl-23702618

ABSTRACT

OBJECTIVE: To assess chlorhexidine absorption and skin tolerability in premature infants, following skin antisepsis with 2% aqueous chlorhexidine gluconate (CHG) prior to peripherally inserted central catheter (PICC) placement. STUDY DESIGN: Neonates less than 32 weeks gestation had skin cleansed with CHG prior to PICC placement. CHG concentrations were measured on serial blood samples. Skin integrity was evaluated for 2 weeks after CHG exposure. RESULT: Twenty infants were enrolled; median gestational age was 28 2/7 weeks (range 24 3/7 to 31 4/7). Ten infants had detectable serum chlorhexidine concentrations (range 1.6 to 206 ng ml(-1)). Seven of these infants had their highest serum concentration 2 to 3 days following exposure. No CHG-related skin irritation occurred in any infant. CONCLUSION: CHG was detected in the blood of preterm infants receiving CHG skin antisepsis for PICC insertion. Highest serum concentrations occurred 2 to 3 days after exposure. Further investigation is needed to determine the clinical relevance of CHG absorption in preterm infants.


Subject(s)
Anti-Infective Agents, Local/pharmacokinetics , Antisepsis , Catheterization, Peripheral , Chlorhexidine/analogs & derivatives , Infant, Premature , Skin Absorption/drug effects , Absorption , Anti-Infective Agents, Local/blood , Antisepsis/methods , Chlorhexidine/blood , Chlorhexidine/pharmacokinetics , Chromatography, Liquid , Female , Humans , Infant Care , Infant, Newborn , Male , Pilot Projects , Tandem Mass Spectrometry
8.
J Perinatol ; 32(1): 4-9, 2012 Jan.
Article in English | MEDLINE | ID: mdl-22031047

ABSTRACT

Chlorhexidine gluconate (CHG) is a widely used topical antiseptic that is recommended by the Centers for Disease Control and Prevention for skin cleansing before central venous catheter insertion in adults and children. Because of limited safety data, CHG is not recommended for use in children <2 months of age. CHG is, however, frequently used in Neonatal Intensive Care Units across the United States. Here, we will review the safety of CHG use in preterm infants.


Subject(s)
Anti-Infective Agents, Local/adverse effects , Antisepsis/methods , Chlorhexidine/analogs & derivatives , Skin Care/adverse effects , Chlorhexidine/adverse effects , Humans , Infant, Newborn , Skin Care/methods
9.
J Biol Chem ; 275(38): 29391-9, 2000 Sep 22.
Article in English | MEDLINE | ID: mdl-10893410

ABSTRACT

Although blood-feeding hookworms infect over a billion people worldwide, little is known about the molecular mechanisms through which these parasitic nematodes cause gastrointestinal hemorrhage and iron deficiency anemia. A cDNA corresponding to a secreted Kunitz type serine protease inhibitor has been cloned from adult Ancylostoma ceylanicum hookworm RNA. The translated sequence of the A. ceylanicum Kunitz type inhibitor 1 (AceKI-1) cDNA predicts a 16-amino acid secretory signal sequence, followed by a 68-amino acid mature protein with a molecular mass of 7889 daltons. Recombinant protein (rAceKI-1) was purified from induced lysates of Escherichia coli transformed with the rAceKI-1/pET 28a plasmid, and in vitro studies demonstrate that rAceKI-1 is a tight binding inhibitor of the serine proteases chymotrypsin, pancreatic elastase, neutrophil elastase, and trypsin. AceKI-1 inhibitory activity is present in soluble protein extracts and excretory/secretory products of adult hookworms but not the infective third stage larvae. The native AceKI-1 inhibitor has been purified to homogeneity from soluble extracts of adult A. ceylanicum using size exclusion and reverse-phase high pressure liquid chromatography. As a potent inhibitor of mammalian intestinal proteases, AceKI-1 may play a role in parasite survival and the pathogenesis of hookworm anemia.


Subject(s)
Ancylostoma , Serine Proteinase Inhibitors , Amino Acid Sequence , Animals , Base Sequence , Hydrolysis , Molecular Sequence Data , Serine Proteinase Inhibitors/genetics , Serine Proteinase Inhibitors/isolation & purification , Serine Proteinase Inhibitors/pharmacology
SELECTION OF CITATIONS
SEARCH DETAIL
...